Damned If You Do, Damned If You Don’t: The Conundrum of Adipose Tissue Vascularization  by Yilmaz, Mustafa & Hotamisligil, Gökhan S.
Cell Metabolism
PreviewsDamned If You Do, Damned If You Don’t:
The Conundrum of Adipose Tissue VascularizationMustafa Yilmaz1 and Go¨khan S. Hotamisligil1,2,*
1Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, MA 02115, USA
2Harvard-MIT Broad Institute, Cambridge, MA 02142, USA
*Correspondence: ghotamis@hsph.harvard.edu
http://dx.doi.org/10.1016/j.cmet.2012.12.014
The plasticity of adipose tissue requires highly regulated changes in accompanying blood vessels. In obesity,
adipose tissue angiogenesis plays a complex role to support tissue growth and promote metabolic disease.
Emerging research (Sung et al., 2013) indicates that exploiting the mediators of adipose tissue angiogenesis
may offer the possibility for therapeutic interventions.Adipose tissue has a profound command
over other metabolic organs and exhibits
remarkable plasticity. During nutrient
excess adipose tissue expands, adopting
a hypertrophic/hyperplastic structure, to
store energy for periods of limited nutrient
availability. Undoubtedly, the expansion
of adipose tissue generates a commensu-
rate increase in oxygen demand. Previous
studies have revealed that adipose tissue
growth (Rupnick et al., 2002) and adipo-
cyte differentiation are reliant on new
vessel development to support proper
supply of oxygen and other nutrients
(Nishimura et al., 2007). Multiple angio-
genic factors such as vascular endothe-
lial, fibroblast, or hepatocyte growth
factors (VEGF, FGF, HGF) and leptin are
mechanisms by which to ensure tissue
homeostasis among adipocytes, adipose
stromal cells, and resident or recruited
immune cells (Cao, 2007). However, in
obesity, the synergy between adipose
tissue expansion and vascularization is
lost, giving rise to inadequate perfusion
of the tissue and hypoxia (Hosogai et al.,
2007). Impaired vascularization may
contribute to metabolic perturbations
as a result of the stress, inflammatory
responses, and dysregulation of adipocy-
tokine production in hypoxic adipose
tissue (Gregor and Hotamisligil, 2007).
Hence, improving vascular network and
reversing hypoxic conditions may be
beneficial. In this issue of Cell Metabo-
lism, Sung et al. demonstrate that modu-
lating VEGF-A production in adipose
tissue protects obese mice against meta-
bolic complications even at later stages of
disease (Sung et al., 2013).
Despite evidence demonstrating the
deleterious effects of decreased angio-genesis in adipose tissue, this ‘‘vascular
story’’ is far from straightforward. Rather,
decreasing the blood supply to obese
adipose tissue has proven beneficial in
obesity and associated complications.
Inhibition of angiogenesis in genetically
obese mice has resulted in substantial
weight loss and metabolic benefits (Rup-
nick et al., 2002). Likewise, treatment
with TNP-470, a synthetic inhibitor of
angiogenesis, reduces adiposity and
normalizes serum insulin and glucose
levels in dietary obesity (Bra˚kenhielm
et al., 2004). Similar results have also
been obtained by targeting blood vessels
specifically in obese white adipose tissue
(WAT) with a proapoptotic peptide, result-
ing in a regression of metabolic abnormal-
ities (Kolonin et al., 2004). Obese adipose
tissue functions similarly to a tumor,
addicted to the blood supply necessary
to maintain its mass and can be amelio-
rated by blocking angiogenesis. These
observations suggest that while a chroni-
cally and incrementally oxygen-deprived
adipose tissue is detrimental for sys-
temic metabolic homeostasis, altogether,
starving obese adipose tissue of oxygen
to the point of death may also create
metabolic benefits in obesity.
To resolve these complexities, recent
studies have employed genetic models
to address the effects of enhanced
adipose tissue vascularization. Overex-
pression of VEGF-A, specifically in
adipose tissue of obese mice, was re-
ported to mitigate hypoxia and inflamma-
tion and improve systemic glucose
metabolism (Sun et al., 2012). These
observations suggest that early stimula-
tion of WAT angiogenesis in obesity can
prevent development of systemic meta-Cell Metabolismbolic aberrations, perhaps by allowing
the sustenance of a healthier adipose
tissue. In another well-designed study,
mice overexpressing VEGF-A exhibited
elevated vascularization in both WAT
and brown adipose tissues (BAT) and
were generally free of metabolic dysfunc-
tion induced by a high-fat diet (HFD), with
reduced adiposity, increased BAT func-
tion, and improved insulin sensitivity (Elias
et al., 2012).
To address stage-dependent effects
of vascularization, Sung et al. utilized
inducible adipose tissue-specific VEGF-A
deletion (VEGFAdD) and overexpression
(VEGFAdTg) models. VEGF deletion re-
sulted in increased adipose tissue inflam-
mation and apoptosis on HFD, pre-
sumably as a consequence of scarce
vasculature and hypoxia. VEGFAdD mice
on HFD also showed systemic insulin
resistance and glucose intolerance, as
well as increased total cholesterol and
liver triglyceride content. Hence, adipose
tissue perturbations induced by reduced
blood supply also have important local
and systemic consequences. Sung et al.
also tested periodic VEGF-A induction
concurrently with HFD challenge. Consis-
tent with previous studies (Sun et al.,
2012), activation of VEGF-A prevented
hypoxia and decreased inflammatory infil-
tration. Interestingly, VEGFAdTg mice were
also less prone to HFD-induced insulin
resistance, despite no differences in
body weight. The metabolic improve-
ments resulting from late-stage VEGF-A
stimulation are also associated with
enhanced vascularization and reduced
hypoxia. Therefore, VEGF-dependent re-
covery of angiogenesis in adipose tissue
and the consequent improvements in17, January 8, 2013 ª2013 Elsevier Inc. 7
Figure 1. Stage-Dependent Effects of Adipose Tissue Vascularization
Adipose tissue undergoes hypertrophic and hyperplastic alterations during the course of obesity, resulting in the accumulation of hypoxic and stressed adipo-
cytes in an inflammatory milieu. At the early stages, suppression of vascularization results in enhanced adipose tissue perturbations such as hypoxia, inflamma-
tion, and apoptosis, eventually leading to systemic insulin resistance. On the contrary, late-stage suppression brings about reduced adiposity and improved
glucose tolerance. This is likely explained by apoptosis-mediated elimination of stressed adipocytes and consequently the regression of adipose tissue.
However, induction of vascularization has beneficial effects at both early and late stages of disease. First, an increase in adipose tissue vascularization results
in decreased hypoxia. Second, enriched vasculature alleviates adipose tissue inflammation and prevents adipocyte apoptosis. Besides these local effects and
impact on systemic adiposity, positive modulation of adipose tissue vascularization improves systemic metabolic abnormalities, such as insulin resistance and
glucose intolerance.
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independent of the timing of expression
(Sung et al., 2013). Another VEGF family
protein, VEGF-B, has also been sug-
gested as a contributor to metabolic
disorders. Inhibition of VEGF-B reduces
glucose intolerance and dyslipidemia
(Hagberg et al., 2012). However, the
protective role of VEGF-B has not been
linked to vascularization, but rather to
reduced fatty acid transport through
endothelial cells, which prevents lipid
accumulation in peripheral tissues. It
remains unknown whether this function
is shared by other VEGF isoforms and8 Cell Metabolism 17, January 8, 2013 ª2013contributes to the phenotypes resulting
from VEGF-A modulation.
Taken together, the results presented in
this current report and those from
previous studies suggest that adipose
tissue vasculature possesses a dual role
in maintaining metabolic homeostasis.
Repressing vascularization during early
stages of adipose tissue expansion in
obesity exacerbates metabolic perturba-
tions (Sun et al., 2012; Sung et al., 2013).
This is possibly due to impaired adipo-
genesis and energy storage capacity, re-
sulting in chronic hypoxia, inflammation,
dysregulation of adipokines, and expo-Elsevier Inc.sure to excess lipids in other tissues
(Hosogai et al., 2007). Conversely, the
disruption of adipose tissue vasculature
in obesity improves metabolic defects
(Kolonin et al., 2004; Sun et al., 2012),
perhaps by mechanistically restricting
access to and subsequently eliminating
malfunctioning adipocytes, and reducing
adiposity to dominate the metabolic
outcome. As shown here, induction of
adipose tissue angiogenesis, early or
late stage, suffices to alleviate metabolic
defects such as glucose intolerance and
hepatosteatosis (Sung et al., 2013)
(Figure 1). However, these intriguing
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remain to be investigated, including the
extent of advantageous vascularization
in adipose tissue, the significance of
BAT vascularization, and the underlying
molecular mechanisms.
Notwithstanding its experimental pro-
mise, a practical translational approach
involving modulation of adipose tissue
vasculature for obesity has not yet com-
menced. The current study paves the
way for potential therapeutic approaches
based on the beneficial effects of inducing
vascularization in adipose tissue, even at
the later stages of obesity. However, sup-
pressing angiogenesis also has potential
as a late-stage intervention. It is intriguing
that a massive and acute decline of
adipose tissue, resulting in death and
demise, is more favorable than chronic
and incremental depletion of oxygen and
nutrients in obesity. It is also curious that
the mechanisms to deal with the massive
exposure to the rather toxic contents ofadipocytes after death are better adapted
to support homeostasis, compared to
those associated with chronic shortages
in nutrient or oxygen supply, which render
this tissue dysfunctional but keep it alive.
These findings are consistent with evolu-
tionary pressures, which allow for devel-
opment of better adaptive metabolic
responses to severe conditions of limited
duration, rather than milder but long-
term exposures to adverse conditions at
this critical metabolic site.REFERENCES
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